Motor-cognitive Performance in People With Multiple Sclerosis
Study Purpose
Having a neurological disease such as multiple sclerosis (MS) leads to difficulties in
balance and gait with or without concurrent performance of cognitive tasks, hindering
activity performance and influencing the possibilities for an independent lifestyle.
The investigators have adapted a previously developed balance training program to a
highly challenging program specifically directed to MS (HiBalance-MS). This program was
recently tested and found feasible in a pilot study. The investigators will now perform a
randomized controlled trial in people with MS, in order to determine the effects of the
program. The hypothesis is that progressively challenging balance exercise programs that
are specific to the balance control domains affected by MS will be effective to improve
balance control, walking, motor-cognitive performance, activity performance and health
related quality of life.
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
No
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
Interventional
Eligible Ages
18 Years - 65 Years
Gender
All
More Inclusion & Exclusion Criteria
Inclusion Criteria:
- an MS diagnosis according to McDonald criteria;
- an overall MS-disability score from 2.0 to 5.5 according to the Expanded Disability
Status Scale;
- ability to walk 100 m without aid;
- a maximum score of 24 in the Mini-BESTest (i.e., < 25 points)
- 18 to 65 years of age.
Exclusion Criteria:
- cognitive impairment as indicated by a score <21 in the Montreal Cognitive
Assessment;
- presence of other conditions that would substantially influence balance;
- an MS relapse or change of disease-modifying treatment within the past 8 weeks
Trial Details
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
N/A
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
Karolinska Institutet
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study.
Sverker Johansson, Ph.D
Principal Investigator Affiliation
Karolinska Institutet, org.nr 202100-2973
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
Other
Overall Status
Recruiting
Countries
Sweden
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied.
Everyday living means being in complex environments and performing complex activities
which usually consist of and require a combination of motor and cognitive skills. Having
a neurological disease such as multiple sclerosis (MS) compromises the motor-cognitive
performance. This leads to difficulties in balance and gait with or without concurrent
performance of cognitive tasks, hindering activity performance and influencing the
possibilities for an independent lifestyle.
The investigators have, in a co-design process with stakeholders, adapted a HiBalance
program, originally developed by the Franzén research group for people with Parkinson's
disease and combining motor-cognitive exercises in a progressively more difficult manner
(HiBalance-PD), to a program specifically developed to MS (HiBalance-MS). The developed
HiBalance-MS program was recently tested and found feasible in a pilot study (results
published 2023). The investigators will now perform a randomized controlled trial in
people with MS, in order to determine the effects of a highly challenging balance
training program (HiBalance-MS) on physical and cognitive functioning, and activity
performance, in this group. The results will have immediate application and clinical
relevance. With improved balance control people with MS will also gain other health
benefits related to an active lifestyle and a better everyday life.
The hypothesis that motor-cognitive performance is reduced and impact activity
performance in people with MS. They also hypothesize that progressively challenging
balance exercise programs that are specific to the balance control domains affected by MS
will be effective to improve balance control, walking, motor-cognitive performance,
activity performance and health related quality of life.
Participants will be recruited through Karolinska University Hospital, through
physiotherapists and physicians specialized in neurology in Stockholm and via
advertisement in newspapers and the patient organization NEURO Sweden. According to
earlier power calculations for detecting effects in balance and gait measures after this
particular intervention, the investigators anticipate 40 to 50 participants in each group
to detect significant changes.
The HiBalance-MS program is based on scientifically well-established principles of
exercise training and postural control. It will be conducted as a progressive
individually adjusted group training to challenge the specific balance deficit of every
participant. Four main sub-systems underlying balance control (stability limits,
anticipatory postural adjustments, sensory integration and motor agility) are used to
target specific balance impairments. To ensure highly challenging exercises, each task is
individually adjusted. Daily variation in capacity will be rated before each training
session and participants will at the end of each session rate the challenging level. The
training will be performed in the clinic (Karolinska University hospital) for an hour,
twice a week for 10 weeks, as a group intervention (6 to 8 participants) facilitated by
two physiotherapists/trainers.
Arms & Interventions
Arms
Experimental: Balance training intervention group
The program HiBalance-MS is based on scientifically well-established principles of
exercise training and postural control. It will be conducted as a progressive
individually adjusted group training to challenge the specific balance deficit of every
participant. To ensure highly challenging exercises, each task is individually adjusted,
e.g., by altering the base of support, increasing speed, restricting vision and varying
grade of multitasking. Daily variation in capacity will be rated before each training
session and participants will at the end of each session rate the challenging level. The
training will be performed in the clinic, at Karolinska University Hospital, for an hour,
twice a week for 10 weeks, as a group intervention including 6 to 8 participants and
facilitated by two physiotherapists/trainers.
No Intervention: No intervention control group
Participants in the control group are encouraged to maintain their normal physical
activities and are not restricted from participation in ongoing rehabilitation programs.
Interventions
Other: - HiBalance-MS
See arm description for intervention group.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
This website uses cookies to improve your user experience. By using this site you agree to our use of cookies. Please read our Privacy Policy to learn more.
Ok